Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet - Reuters
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet Reuters
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet Reuters
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet Reuters
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet Reuters